UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Immunocore Holdings plc

(Name of Issuer)

Ordinary Shares, nominal value £0.002 per share (Title of Class of Securities)

45258D105** (CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

8.

Shared Dispositive Power: 2,358,650

- " Rule 13d-1(b)
- " Rule 13d-1(c)
- x Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**This CUSIP number applies to the Issuer's American Depositary Shares ("ADSs"). Each one ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.

Schedule 13G Page 2 of 7 CUSIP No. 45258D105 1. Name of Reporting Person: Ian Michael Laing 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization: United Kingdom 5. Sole Voting Power: 0 Number of Shares 6. Shared Voting Power: 2,358,650 Beneficially Owned by Each 7. Sole Dispositive Power: 0 Reporting Person With:

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

	10.	Check if the A	regate Amount in Row (9) Excludes Certain Shares (See Instructions)"
	11.	* The percent	Represented by Amount in Row (9): 5.4%* 'the class reported is based on 43,841,931 Ordinary Shares of the Issuer outstanding as of September 30, 2021, as set forth in the Issuer's on November 10, 2021.
	12.	Type of Repor	g Person (See Instructions): IN
	lule 13G		Page 3 of
JUSI	P No. 452		
	1.	Name of Repor	ng Person: Caroline Elizabeth Laing
	2.	Check the App	priate Box if a Member of a Group (See Instructions)
		(a) x	
		(b) "	
	3.	SEC Use Only	
	4.	Citizenship or United Kingdo	ace of Organization:
			5. Sole Voting Power: 0
	Number Shares Benefit Owner	cially I by	6. Shared Voting Power: 2,358,650
	Each Report Person		7. Sole Dispositive Power: 0
			8. Shared Dispositive Power: 2,358,650
	9.	Aggregate Am	ant Beneficially Owned by Each Reporting Person: 2,358,650
	10.	Check if the A	regate Amount in Row (9) Excludes Certain Shares (See Instructions)"
	11.	* The percent	Represented by Amount in Row (9): 5.4%* 'the class reported is based on 43,841,931 Ordinary Shares of the Issuer outstanding as of September 30, 2021, as set forth in the Issuer's on November 10, 2021.
	12.	Type of Repor	g Person (See Instructions): IN

Schedule 13G Page 4 of 7

Item 1. (a) Name of Issuer:

9.

Aggregate Amount Beneficially Owned by Each Reporting Person: 2,358,650

Immunocore Holdings plc

Item 1. (b) Address of Issuer's Principal Executive Offices:
92 Park Drive, Milton Park
Abjugdon, Oxfordshira OX14 4PV

Abingdon, Oxfordshire OX14 4RY United Kingdom Item 2. (a) Names of Persons Filing:

1. Ian Michael Laing

2. Caroline Elizabeth Laing

Item 2. (b) Address of Principal Business Office or, if none, Residence:

4 Charlbury Road Oxford OX2 6UT United Kingdom

Item 2. (c) Citizenship:

Ian Michael Laing and Caroline Elizabeth Laing are citizens of the United Kingdom.

Item 2. (d) Title of Class of Securities:

Ordinary Shares, nominal value £0.002 per share

Item 2. (e) CUSIP Number:

45258D105

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership

Item 4. (a) Amount Beneficially Owned:

Ian Michael Laing and Caroline Elizabeth Laing may be deemed to beneficially own, in the aggregate, 2,358,650 Ordinary Shares, nominal value £0.002 per share (the "Shares"), of which 1,915,140 Ordinary Shares are held by Ian Michael Laing and 443,510 Ordinary Shares are held by Caroline Elizabeth Laing.

Item 4. (b) Percent of Class:

The Shares represent approximately 5.4% of the Issuer's Ordinary Shares outstanding, based on 43,841,931 Ordinary Shares of the Issuer outstanding as of September 30, 2021, as set forth in the Issuer's Form 6-K, filed on November 10, 2021.

Item 4. (c) Number of shares as to which such person has:

Ian Michael Laing and Caroline Élizabeth Laing each have shared voting power and shared dispositive power in respect of 2,358,650 Ordinary Shares representing 5.4% of the Issuer's Ordinary Shares outstanding. Ian Michael Laing and Caroline Elizabeth Laing are husband and wife, and may be deemed to beneficially own the Ordinary Shares beneficially owned by the other person.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable.

Schedule 13G Page 5 of 7

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control

Person

Not applicable.

Item 8. Identification and Classification of Members of the Group

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certifications

Not applicable.

Schedule 13G Page 6 of 7

IAN MICHAEL LAING

By: /s/ Ian Michael Laing
Name: Ian Michael Laing

CAROLINE ELIZABETH LAING

By: /s/ Caroline Elizabeth Laing
Name: Caroline Elizabeth Laing

Schedule 13G Page 7 of 7

LIST OF EXHIBITS

Exhibit No.	Description
<u>99.1</u>	Identification of Members of the Group
99.2	Joint Filing Agreement, dated February 18, 2022, entered into by Ian Michael Laing and Caroline Elizabeth Laing.

IDENTIFICATION OF MEMBERS OF THE GROUP

The members of the group filing the statement on Schedule 13G with respect to the Ordinary Shares, nominal value £0.002 per share, of Immunocore Holdings plc, dated as of February 18, 2022, of which this Exhibit 1 is a part, are as follows:

Ian Michael Laing

Caroline Elizabeth Laing

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares, nominal value £0.002 per share, of Immunocore Holdings plc, dated as of February 18, 2022 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 18, 2022

IAN MICHAEL LAING

By: /s/ Ian Michael Laing

Name: Ian Michael Laing

CAROLINE ELIZABETH LAING

/s/ Caroline Elizabeth Laing

Name: Caroline Elizabeth Laing